Loqtorzi: Side Effects & Dosing

Information is sourced from publicly available references. The information is for educational purpose of healthcare professionals and we are not liable for any loss or damage.

Core Prescribing Info

Contents

Toripalimab

Indications/Uses

1st-line treatment of adult patients w/ recurrent, not amenable to surgery or RT, or metastatic nasopharyngeal carcinoma in combination w/ cisplatin & gemcitabine.

Dosage/Direction for Use

IV 240 mg every 3 wk. Administer initial dose as 60-min infusion & subsequent doses as 30-min infusion if tolerated. Continue until disease progression, unacceptable toxicity or up to max duration of 24 mth.

Contraindications

Severe hypersensitivity.

MIMS Class

Targeted Cancer Therapy

ATC Classification

L01FF13 - toripalimab ; Belongs to the class of PD-1/PD-L1 (Programmed cell death protein 1/death ligand 1) inhibitors. Used in the treatment of cancer.

Regulatory Classification

POM

Presentation/Packing

Form

Loqtorzi conc for soln for infusion 240 mg/6 mL

Packing/Price

1's

Loqtorzi

Manufacturer:

Suzhou Union Biopharm